Crossmark

Reply to Martorell Calatayud et al., “Cost-Consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-Severe Hidradenitis Suppurativa”

Crossref DOI link: https://doi.org/10.1016/j.ad.2026.104665

Published Print: 2026-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Romaní, J. https://orcid.org/0000-0002-6134-5155
License Information

Text and Data Mining valid from 2026-09-01

Text and Data Mining valid from 2026-09-01

Version of Record valid from 2026-04-15
More Information

This article is maintained by: Elsevier

Article Title: Reply to Martorell Calatayud et al., “Cost-Consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-Severe Hidradenitis Suppurativa”

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2026.104665

Content Type: simple-article

Copyright: © 2026 AEDV. Published by Elsevier España, S.L.U.